When discussing the operation of pancreatic cancer, the first reality that emerges is that of selection: the vast majority of patients are not eligible for surgery at the time of diagnosis. The tumor is often discovered at a late stage, with vascular invasion or metastases that make resection impossible.
For patients who undergo surgery, the question of the actual chances of recovery deserves to be asked precisely, beyond the simple five-year survival rate.
Related reading : How to Choose the Right Vehicle Inspection Center in Switzerland
Early death after pancreatic resection: an underestimated risk
One might think that the hardest part is over once the tumor is removed. Recent data shows the opposite for a significant fraction of operated patients.
A study involving a cohort of 418 patients treated with neoadjuvant chemotherapy followed by resection highlighted a specific phenomenon: 10.5% of operated patients die within twelve months following the intervention, from causes directly related to cancer. Despite curative surgery, these patients have a very short median survival.
Related reading : Practical Guide: How to Install Home Air Conditioning Step by Step
This risk of early death is now identified as a distinct clinical problem. Simple criteria allow for the identification of the most exposed profiles even before the operation. For surgical teams, the challenge is to better select candidates for resection and avoid a heavy intervention whose benefit would be negated by a rapid relapse.
The cure of pancreatic cancer after surgery therefore depends as much on the quality of preoperative selection as on the surgical procedure itself.
Five-year survival and probability of cure: two different concepts
Five-year survival rates are the usual reference. But they do not indicate how many patients are actually cured, meaning free from the risk of relapse related to the disease.
Recent studies have attempted to quantify this distinction. According to these analyses, about a quarter of operated patients could be considered statistically cured. This figure particularly concerns those who received neoadjuvant chemotherapy before resection.
The difference between “being alive at five years” and “no longer having an excess risk of death related to cancer” is fundamental. A patient alive at five years may still relapse. A statistically cured patient has joined the life expectancy of the general population of the same age. This distinction changes the way patients and their families are informed about the actual prognosis.
Neoadjuvant chemotherapy before pancreatic surgery: the impact on outcomes
To operate immediately or to treat first with chemotherapy before going to surgery: this choice has measurable consequences on postoperative outcomes.
What prior chemotherapy concretely changes
Neoadjuvant chemotherapy aims for several simultaneous objectives:
- Reduce tumor volume to make resection more complete, especially when the tumor is classified as “borderline” or locally advanced
- Test the biology of the tumor: if cancer progresses despite chemotherapy, resection would likely not provide lasting benefit
- Early treatment of micrometastases invisible on imaging, which are responsible for the majority of relapses after surgery
For tumors initially deemed unresectable due to vascular invasion, induction chemotherapy sometimes makes surgery possible. This is a paradigm shift from the historical approach where only immediately operable tumors went to surgery.
The limits to keep in mind
Neoadjuvant chemotherapy is not a guarantee. Some patients do not tolerate the treatment or see their general condition deteriorate to the point of no longer being operable. Feedback on this point varies according to centers and protocols used. The assessment of treatment response relies on imaging, which does not always accurately capture the biological reality of the tumor.
Resectability criteria and selection of operable patients
The operability of pancreatic cancer is not just about the size of the tumor. The medical team evaluates several parameters that directly affect the chances of success.
- Vascular invasion: a tumor encasing the superior mesenteric artery or the celiac trunk beyond a certain threshold is classified as unresectable from the outset
- The absence of distant metastases, verified by CT scan and sometimes by exploratory laparoscopy before resection
- The general condition of the patient: cardiac, hepatic, renal, and pulmonary functions must support a long and technically demanding intervention
- The response to neoadjuvant chemotherapy for borderline tumors, assessed by imaging and biological markers
In practice, only a minority of diagnosed patients meet all these criteria. The vast majority of pancreatic cancers are discovered at a stage where surgery is not feasible, which explains the overall grim prognosis of this disease.
Postoperative follow-up and detection of relapse
After pancreatic resection, follow-up is strict. Relapses most often occur within the first two years, in the form of liver metastases or local recurrence.
The monitoring protocol combines regular imaging and measurement of the CA 19-9 marker. An increase in this marker often precedes visible relapse on a scan. The frequency of checks is generally quarterly in the first year, then gradually spaced out.
Adjuvant chemotherapy, administered after surgery, is part of the standard treatment. It aims to eliminate residual tumor cells and delay or prevent relapse. Its benefit is documented, but it is not sufficient on its own to guarantee a cure.
Patients who reach the five-year mark without relapse see their risk of cancer-related death decrease significantly. For those who were operated on after neoadjuvant chemotherapy with healthy resection margins, the long-term prognosis is the most favorable among all patients with pancreatic cancer.